Amphista Therapeutics announces AMX-883 data to be presented at the ASH Annual Meeting and Exposition and provides a business progress update

On November 25, 2025 Amphista Therapeutics ("the Company" or "Amphista"), a leader in the discovery of next generation targeted protein degradation (TPD) medicines, reported the presentation of new preclinical data with its lead Targeted Glue AMX-883, an orally bioavailable, potent and selective degrader of BRD9 at the upcoming 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition in Orlando, Florida, 6-9 December 2025, and provides a business progress update ahead of its leadership team attending the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, 12-15 January 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract reports:

AMX-883 time dependently increases the expression of key proteins associated with myeloid cell differentiation and maturation in vitro.
Using patient derived samples in disseminated xenograft models, AMX-883 significantly reduced leukemic burden in bone marrow and blood over the treatment period and resulted in a significant increase in survival compared to venetoclax.
The combination of AMX-883 with venetoclax resulted in synergistic efficacy in leukemic cell lines. AMX-883 co-dosed with venetoclax and azacitidine resulted in synergy with significant cell death at therapeutically relevant concentrations. Combination benefit was also observed with a range of other commonly used AML therapies in vitro.
A cell line co-cultured with venetoclax and AMX-883 did not develop resistance to venetoclax and had comparable sensitivity to cells on their first exposure to venetoclax. The venetoclax-resistant line exhibited a significant increase in the anti-apoptotic proteins MCL-1 and BCL-2, an effect that was prevented when AMX-883 was included during venetoclax treatment.
The data demonstrates the potent, selective BRD9 degrader AMX-883 induces significant differentiation and preclinical efficacy in AML cell lines and in primary AML cell lines.
"There is a critical unmet need for novel therapies that can augment the efficacy of anti-proliferative and cytotoxic agents in AML. The data to be presented at ASH (Free ASH Whitepaper) demonstrates that AMX-883 prevented the development of resistance to venetoclax in vitro and AMX-883 delivered synergistic efficacy when combined with venetoclax, achieving significant cancer cell death at therapeutically relevant concentrations," said Martin Pass, Chief Development Officer at Amphista Therapeutics. "These compelling results provide further strong preclinical evidence supporting the advancement of AMX-883 into the clinic for AML patients."

"Amphista has made significant progress this year in advancing a new generation of targeted protein degraders designed to address serious diseases with high unmet need," said Antony Mattessich, Chief Executive Officer of Amphista Therapeutics. "This is exemplified by the key data to be presented at ASH (Free ASH Whitepaper), alongside the nomination of AMX-883 as our first clinical candidate and the unveiling of distinct mechanisms of action across BRD9, SMARCA2, and TEAD. We look forward to 2026 when we will advance AMX-883 into the clinic and nominate our next clinical candidates."

2025 business highlights:

Nominated AMX-883, an orally available Targeted Glue degrader of BRD9, as the Company’s first clinical development candidate for the treatment of AML.
Amphista received additional funding as part of its Series B financing following AMX-883 nomination, supporting plans to initiate the Company’s first clinical trial in H2 2026.
Disclosed a novel mechanism of action for TEAD degradation by selectively inducing its proximity to FBXO22 as a targeted molecular glue, resulting in strong and rapid degradation.
Reported first data from the SMARCA2 program, demonstrating exquisite selectivity of Amphista’s bifunctional Targeted Glues for SMARCA2 over the closely related homolog, SMARCA4.
Achieved a discovery milestone under Amphista’s exclusive research collaboration and license agreement with Merck KGaA.
Showcased Amphista’s cryo-EM enabled Eclipsys platform at SLAS Europe 2025, highlighting its unique approach to constructing novel, orally bioavailable Targeted Glue degraders with mechanisms distinct from traditional cereblon (CRBN) or VHL approaches.
Presented a differentiated mechanism for BRD9 degradation distinct from CRBN- or VHL-based PROTACs using Amphista’s Targeted Glue technology at the 2nd SMR Molecular Glues Meeting and the 5th Annual TPD and Induced Proximity Summit Europe.
Poster presentation details:

Title: AMX-883, a Potent and Selective Degrader of BRD9 Drives Differentiation in Acute Myeloid Leukaemia and Shows Synergistic Efficacy in Combination with venetoclax In Vivo and Prevents the Emergence of Resistance to venetoclax In Vitro.
Speaker: Martin Pass
Session Name: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster I
Session Date and Time: December 6, 2025 at 5:30 PM – 7:30 PM
Room: OCCC – West Halls B3-B4
Presentation ID: 1489
Abstract Number: abs25-2358

The online abstract is available on the ASH (Free ASH Whitepaper) website here.

Ends

About BRD9 and Acute Myeloid Leukaemia

Acute myeloid leukaemia (AML) is one of the most aggressive blood cancers and despite the availability of anti-proliferative treatments, patient survival rates remain alarmingly low. The disease is characterized by a differentiation block which prevents myeloid cell maturation and results in an accumulation of immature cells/AML blasts. Therapies which remove the differentiation block and allow maturation of these AML blasts including ATRA, FLT-3 inhibitors, and most recently Menin inhibitors have demonstrated clinical benefit in several sub-sets of AML. However, there is a pressing need for broader-acting treatments that can benefit patients regardless of their genetic profile.

BRD9 is a subunit of the non-canonical BAF complex where it plays a key structural and functional role, being linked to regulation of chromatin structure and maintaining genomic stability in AML. Degradation of BRD9 releases the differentiation block and leads to the differentiation and death of AML blasts.

(Press release, Amphista Therapeutics, NOV 25, 2025, View Source [SID1234660929])

Alkermes to Participate in Two Upcoming Investor Conferences

On November 25, 2025 Alkermes plc (Nasdaq: ALKS) reported that management will participate in two upcoming investor conferences.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

8th Annual Evercore Healthcare Conference
Date/Time: Wednesday, Dec. 3, 2025 at 2:10 p.m. ET (7:10 p.m. GMT)

Piper Sandler 37th Annual Healthcare Conference
Date/Time: Thursday, Dec. 4, 2025 at 12:00 p.m. ET (5:00 p.m. GMT)

The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

(Press release, Alkermes, NOV 25, 2025, View Source [SID1234660928])

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

On November 25, 2025 Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, reported that Dr. Neal Walker, Aclaris’ Chief Executive Officer and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Piper Sandler 37th Annual Healthcare Conference in New York City. The discussion will take place on Tuesday December 2, 2025 at 11:00 AM EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live and archived webcast will be accessible on the Events page of View Source The webcast will be available on the Aclaris website for at least 30 days.

(Press release, Aclaris Therapeutics, NOV 25, 2025, View Source [SID1234660927])

Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS

On November 25, 2025 Novartis reported it will present data from over 70 abstracts, including investigator-initiated trials at the 67th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting & Exposition and 2025 San Antonio Breast Cancer Symposium (SABCS). Featured among these latest advances in hematology and oncology are 11 oral presentations, with the Phase III VAYHIT2 trial for ianalumab in immune thrombocytopenia (ITP) accepted as a late-breaker abstract.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"For decades, Novartis has redefined the future of hematology and oncology, and we’re building on that foundation with compelling new data presented at ASH (Free ASH Whitepaper) and SABCS," said Mark Rutstein, M.D., Global Head, Oncology Development, Novartis. "These data underscore how we seek to set new standards for transformative care, with the aim of turning cutting-edge innovation into meaningful impact for patients."

Key highlights of data accepted by ASH (Free ASH Whitepaper) include:

Abstract Title Abstract Number/ Presentation Details
Ianalumab (VAY736)
Primary results from VAYHIT2, a randomized, double-blind, Phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment Abstract #LBA-2
Oral Presentation
December 9, 7:45 – 8:00 am ET
Secondary analysis results from VAYHIT3, a Phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy Abstract #844
Oral Presentation
December 8, 3:30 – 3:45 pm ET
Scemblix (asciminib)
Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis Abstract #1997
Poster Presentation
December 6, 5:30 – 7:30 pm ET
Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial Abstract #5549
Poster Presentation
December 8, 6:00 – 8:00 pm ET
Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (TKI) Abstract #906
Oral Presentation
December 8, 4:00 – 4:15 pm ET
A comparison of real-world outcomes of asciminib versus ATP-competitive tyrosine kinase inhibitors as second-line treatment in patients with chronic myeloid leukemia in chronic phase Abstract #724
Oral Presentation
December 7, 5:15 – 5:30 pm ET
Pelabresib (DAK539)
Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study Abstract #910
Oral Presentation
December 8, 3:30 – 3:45pm ET
Rapcabtagene autoleucel (YTB323)
Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: phase II interim results Abstract #670
Oral Presentation
December 7, 5:15 – 5:30 pm ET
Fabhalta (iptacopan)
Oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin increases in patients with paroxysmal nocturnal hemoglobinuria with baseline hemoglobin levels 10 to <12 g/dL on anti-C5 therapy: Subgroup analysis of the APPULSE-PNH Phase 3b trial Abstract #4981
Poster Presentation
December 8, 6:00 – 8:00 pm ET
Long-term safety and efficacy of iptacopan in patients with paroxysmal nocturnal hemoglobinuria: 4- and 5-year follow-up of patients from phase 2 studies who entered the roll-over extension program Abstract #3198
Poster Presentation
December 7, 6:00 – 8:00 pm ET
The 2-year efficacy and safety of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria with a history of aplastic anemia on concomitant immunosuppressive therapy who entered the roll-over extension program Abstract #4978
Poster Presentation
December 8, 6:00 – 8:00 pm ET

Key highlights of data accepted by SABCS include:

Kisqali (ribociclib)
Pooled analysis of patients (pts) treated with 1st-line (1L) ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) studies: long-term progression-free survival (PFS) Abstract # PD5-10
Poster Spotlight Presentation
December 11, 8:09 – 8:12 am CST
Five-year analysis of distant disease-free survival (DDFS) across key subgroups from the phase 3 NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2− early breast cancer (EBC) Abstract # PS3-09-08
Poster Presentation
December 11, 12:30 – 2:00 pm CST
Progression-free survival (PFS) and overall survival (OS) results from the phase 3 MONALEESA-3 trial of postmenopausal patients with hormone receptor–positive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL): A subgroup analysis of patients with invasive lobular carcinoma (ILC) Abstract # PS1-10-27
Poster Presentation
December 10, 12:30 – 2:00 pm CST
Ribociclib drug-drug interaction and concomitant medication management in early and advanced breast cancer patients Abstract # PS3-09-15
Poster Presentation
December 11, 12:30 – 2:00 pm CST
Real-world patient (pt) and caregiver experiences with breast cancer (BC) risk of recurrence (ROR) in the US: Results of an Online Survey and Social Media Analysis Abstract # PS1-04-17
Poster Presentation
December 10, 12:30 – 2:00 pm CST
Repower: a real-world noninterventional study of outcomes and experiences in patients with hormone receptor-positive (HR+)/human epidermal growth fact receptor 2-negative (HER2−) early breast cancer (EBC) treated with an adjuvant cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) plus endocrine therapy (ET) Abstract # PS3-08-27
Poster Presentation
December 11, 12:30 – 2:00 pm CST

(Press release, Novartis, NOV 25, 2025, View Source [SID1234660913])

Theralase(R) Announces Brokered LIFE Financing to Further Advance its Phase II Non-Muscle Invasive Bladder Cancer Clinical Study

On November 24, 2025 Theralase Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses reported that it has entered into an agreement with Research Capital Corporation ("RCC") as the sole agent and bookrunner on a commercially reasonable "best efforts" agency basis, for a brokered private placement offering ("Offering") of units of the Company ("Units") at a price of C$ 0.17 per Unit to raise a minimum of C$ 4,500,000 and up to a maximum of C$5,500,000 in aggregate gross proceeds.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Each Unit will consist of one common share of the Company ("Common Share") and one Common Share purchase warrant ("Warrant"). Each Warrant shall entitle the holder thereof to purchase one Common Share ("Warrant Share") at an exercise price of $CAN 0.21 per Warrant Share at any time for a period of 60 months following the closing of the Offering. The Company will use commercial reasonable efforts to obtain the necessary approvals to list the Warrants on the TSX Venture Exchange ("TSXV").

The Company will grant the Agent an option ("Agent’s Option") to increase the size of the Offering by up to C$1,000,000 in Units by giving written notice of the exercise of the Agent’s Option, or a part thereof, to the Company at any time up to 48 hours prior to closing of the Offering.

The Company plans to use the minimum proceeds of the financing for:

Furtherance of a Phase II non-muscle invasive bladder cancer clinical study
Good Laboratory Practice ("GLP") toxicology studies to support clinical development for the intravenous use of Rutherrin (Ruvidar + transferrin) in the treatment of various cancers
working capital and general corporate purposes
If the maximum proceeds are achieved, then the following strategic initiatives will be added:

GLP toxicology studies to support clinical development for the topical use of Ruvidar in the treatment of herpes simplex virus induced cold sores
design, development and commercialization of products in the device division
The Offering is scheduled to close on or about the week of December 1, 2025, or such other date as the Company and the Agent may agree upon, and is subject to the receipt of all necessary approvals; including, the approval of the TSXV.

The Offering will take place by way of:

a private placement pursuant to National Instrument 45-106 – Prospectus Exemptions under Part 5A, as amended by CSA Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption ("Listed Issuer Financing Exemption" or "LIFE"), to qualified investors in all the provinces of Canada, except Québec and
in other jurisdictions where the Offering can lawfully be made; including, the United States under applicable private placement exemptions. Such sales to investors in the United States will be subject to applicable United States securities laws and restrictions on its securities purchased.
The Units issued under the Listed Issuer Financing Exemption will not be subject to resale restrictions pursuant to applicable Canadian securities laws.

The LIFE offering document ("Offering Document") related to the Offering can be accessed under the Company’s profile at www.sedarplus.ca or on the Company’s website at: www.theralase.com.

Prospective investors should read this Offering Document before making an investment decision.

Upon closing of the Offering, the Company shall pay to RCC:

a cash commission equal to 7% of the aggregate gross proceeds of the Offering payable in cash (subject to a reduction for orders on the "president’s list"); and
non-transferrable broker warrants of the Company exercisable to acquire that number of Units equal to 7% of the number of Units issued under the Offering (subject to a reduction for orders on the "president’s list"), at an exercise price of C$0.17 per Unit, expiring 60 months after the date of the closing of the Offering.

(Press release, Theralase, NOV 24, 2025, View Source [SID1234661918])